Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow TVRD by emailGet an email when TVRD pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about TVRD, unsubscribe in one click. Privacy
📣 What TVRD Says Is Next
third quarter of 2027 · “Tvardi anticipates that its existing cash, cash equivalents and short-term investments will be sufficient to fund operations, as currently planned, through the HCC topline readout into the third quarter of 2027.”
Company press release, Aug 14, 2026 · SEC filing
in 2027 · “This is what led us to prioritize UC as our initial indication for TTI-109.” Planned UC Clinical Trial Tvardi plans to initiate a study of TTI-109 in patients with moderate-to-severe UC in 2027, subject to clearance of Investigational New Drug (IND) application and additional funding.”
Company press release, Jul 30, 2026 · SEC filing
Q4 2026 · “As of March 31, 2026 37 Financial Overview and Milestones Select Corporate Information TVRD Ticker Houston, TX HQ 9,381,344 Shares Outstanding 1 $25.0 M Cash / Cash Equivalents / ST Investments 1 Milestones Data Reported from TTI - 109 Phase 1 Healthy Volunteer Trial July 2026 Topline Data from TTI - 101 Phase 1b/2 HCC Trial 2H 2026 Anticipated Cash Runway Expected to Fund Tvardi’s Operating Plan into Q4 2026 Appendix A.”
Company press release, Jul 7, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full TVRD picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for TVRD and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.